Structure–Activity Relationships and Antiplasmodial Potencies of Novel 3,4-Disubstituted 1,2,5-Oxadiazoles

Abstract

The 4-substituted 3-amino-1,2,5-oxadiazole 1 from the Malaria Box Project of the Medicines for Malaria Venture foundation shows very promising selectivity and in vitro activity against Plasmodium falciparum. Within the first series of new compounds, various 3-acylamino analogs were prepared. This paper now focuses on the investigation of the importance of the aromatic substituent in ring position 4. A number of new structure–activity relationships were elaborated, showing that antiplasmodial activity and selectivity strongly depend on the substitution pattern of the 4-phenyl moiety. In addition, physicochemical parameters relevant for drug development were calculated (logP and ligand efficiency) or determined experimentally (CYP3A4-inhibition and aqueous solubility). N-[4-(3-ethoxy-4-methoxyphenyl)-1,2,5-oxadiazol-3-yl]-3-methylbenzamide 51 showed high in vitro activity against the chloroquine-sensitive strain NF54 of P. falciparum (PfNF54 IC50 = 0.034 µM), resulting in a very promising selectivity index of 1526.

Bioactive Oxadiazoles 3.0

“…The research fields explored in this Special Issue include the discovery of new compounds with various biological activities such as: antibacterial 1,2,4-oxadiazole derivatives [ 14 ], antiplasmodial 1,2,5-oxadiazoles [ 15 ], 1,2,4-oxadiazole derivatives as nematicides [ 16 ] and 1,3,4-oxadiazoles with anticancer activity [ 17 ]. Moreover, the synthetic accessibility of bioactive 1,2,4-oxadiazoles at room temperature, was reviewed [ 18 ].…”